Freedom Broker maintains Viemed Healthcare at Hold, lowers price target to $10 from $11

Freedom Broker kept Viemed Healthcare at Hold, reducing its price target to $10 from $11, a 9.1% cut. This implies a 9.5% upside from the Nov 6 close of $9.13.

Original reporting
Published Nov 9, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Freedom Broker maintains Viemed Healthcare at Hold, lowers price target to $10 from $11 — source image
Decision brief

The 30-second read

$VMDBearishLow
01

Why it matters

The downgrade reflects a modestly negative outlook but does not constitute a material event.

02

Market read

Limited to Viemed Healthcare; broader market impact minimal.

03

What to watch

No mention of recent clinical trial updates that could offset the downgrade.

Relevance 5/10Novelty 5/10Timing: pre‑market today

Background

Analyst rating changes are common for micro‑cap biotech firms and can prompt short‑term price moves.

Company-level read

Ticker impact

$VMDBearishMedium confidence
Context

Freedom Broker lowered Viemed Healthcare's price target to $10 from $11, indicating a fresh analyst downgrade.

Expected impact

likely downward pressure as investors price in the lower target.

Evidence & confidence

Target reduction signals weaker outlook; no other catalyst present.

Market effects

Minor impact on small‑cap biotech sector; similar stocks may see slight reassessment.

Limited to US micro‑cap market.

Low global relevance.

Counterpoint

Target cut may be overly cautious; upside potential remains if upcoming trial data beats expectations.

Key entities

  • Freedom Broker

    Equity research firm issuing the rating change.

  • Viemed Healthcare

    US‑listed biotech company (ticker VMD).

Related articles

$VMDMedAI 8/10

Viemed Healthcare Q3 Earnings Call Highlights

VieMed Healthcare (VMD) reported Q3 operating cash flow of $11.5M and free cash flow of $4M. The company expects Q4 improvements in collections and active ventilator patients. Full-year revenue guidance was raised to $316M-$320M, while adjusted EBITDA was narrowed to $64M-$66M. VieMed had $9.7M in cash and $5.3M in borrowings at Q3's end, with a $1M share buyback and $2M term-loan repayment in October.

$VMDMed

Viemed Healthcare Inc (VMD) (Q3 2026) Earnings Call Highlights: Record Revenue

Viemed Healthcare reported Q3 2026 record revenue of $80M. CEO Casey Boyd discussed state rollout timelines, expecting gradual growth. CFO Trey Fitzgerald addressed sequential growth gaps, seasonal trends, and financial KPIs, targeting EBITDA above 20%. Accounts receivable delays impacted cash flow but are expected to resolve in Q4. Boyd also updated on sales force training, M&A pipeline, and patient education progress.

$VMDMed

VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

VIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (November 4, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, an

$VMDMedAI 8/10

Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions